

# Chiara Briani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1453926/publications.pdf>

Version: 2024-02-01

102  
papers

3,345  
citations

168829

31  
h-index

182931

54  
g-index

102  
all docs

102  
docs citations

102  
times ranked

3115  
citing authors

#	ARTICLE	IF	CITATIONS
1	A diagnostic score for anti-myelin-associated glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti-myelin-associated glycoprotein antibody. <i>European Journal of Neurology</i> , 2023, 30, 501-510.	1.7	9
2	Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis. <i>Journal of Neurology</i> , 2022, 269, 1905-1912.	1.8	13
3	Update on therapy of chronic immune-mediated neuropathies. <i>Neurological Sciences</i> , 2022, 43, 605-614.	0.9	13
4	Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database. <i>Neurological Sciences</i> , 2022, 43, 3939-3947.	0.9	9
5	Oligoclonal bands: clinical utility and interpretation cues. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2022, 59, 391-404.	2.7	15
6	Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 823812.	1.3	5
7	From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance. <i>Cancers</i> , 2022, 14, 1562.	1.7	9
8	Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies. <i>Neurotherapeutics</i> , 2022, 19, 874-884.	2.1	10
9	Small Fibre Peripheral Alterations Following COVID-19 Detected by Corneal Confocal Microscopy. <i>Journal of Personalized Medicine</i> , 2022, 12, 563.	1.1	7
10	Autonomic dysfunction as first presentation of Glu54Gln transthyretin amyloidosis. <i>Journal of the Neurological Sciences</i> , 2022, 437, 120264.	0.3	0
11	The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	13
12	<sc>Guillain-Barré syndrome and <sc>COVID-19: A 1-year observational multicenter study. <i>European Journal of Neurology</i> , 2022, 29, 3358-3367.	1.7	20
13	Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 751-756.	0.9	135
14	Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers. <i>Journal of Neurology</i> , 2021, 268, 189-198.	1.8	38
15	Pure sensory neuralgic amyotrophy in <sc>COVID-19 infection. <i>Muscle and Nerve</i> , 2021, 63, E7-E8.	1.0	33
16	Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria?. <i>European Journal of Neurology</i> , 2021, 28, 620-629.	1.7	15
17	Mechanisms of Nerve Damage in Neuropathies Associated with Hematological Diseases: Lesson from Nerve Biopsies. <i>Brain Sciences</i> , 2021, 11, 132.	1.1	8
18	Heterogeneous clinical and imaging findings and long-term prognosis in patients with neurolymphomatosis. <i>Muscle and Nerve</i> , 2021, 63, E24-E26.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Nerve ultrasonography features in hereditary transthyretin amyloidosis with V30M mutation and polyneuropathy. <i>Neurological Sciences</i> , 2021, 42, 2547-2548.	0.9	2
20	Acute and chronic inflammatory neuropathies and COVID-19 vaccines: Practical recommendations from the task force of the Italian Peripheral Nervous System Association (<sc>ASNP</sc>). <i>Journal of the Peripheral Nervous System</i> , 2021, 26, 148-154.	1.4	15
21	Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 969-974.	0.9	10
22	The neurophysiological lesson from the Italian CIDP database. <i>Neurological Sciences</i> , 2021, , 1.	0.9	3
23	Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP. <i>Journal of Neurology</i> , 2021, , 1.	1.8	1
24	Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. <i>Neurology</i> , 2021, 97, e660-e672.	1.5	16
25	Limbic Encephalitis with HU-Antibodies in T-cell Anaplastic Lymphoma. A Case Report. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 6548.	1.3	2
26	Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. <i>Brain</i> , 2021, 144, 3392-3404.	3.7	39
27	Leukocytoclastic vasculitis associated with multifocal sensory neuropathy responsive to intravenous immunoglobulins: a case report. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021022.	0.2	0
28	Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. <i>European Journal of Neurology</i> , 2020, 27, 136-143.	1.7	27
29	Immunomodulatory drugs in plasma cell diseases: everything has its price. <i>Leukemia and Lymphoma</i> , 2020, 61, 206-208.	0.6	0
30	Sporadic hereditary neuropathies misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: Pitfalls and red flags. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 19-26.	1.4	12
31	From pathogenesis to personalized treatments of neuropathies in hematological malignancies. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 212-221.	1.4	7
32	Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1092-1099.	0.9	22
33	Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 348.	1.2	22
34	Impact of environmental factors and physical activity on disability and quality of life in CIDP. <i>Journal of Neurology</i> , 2020, 267, 2683-2691.	1.8	4
35	Sural nerve biopsy: current role and comparison with serum neurofilament light chain levels. <i>Journal of Neurology</i> , 2020, 267, 2881-2887.	1.8	13
36	Neurolymphomatosis, a rare manifestation of peripheral nerve involvement in lymphomas: Suggestive features and diagnostic challenges. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 312-315.	1.4	11

#	ARTICLE	IF	CITATIONS
37	Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	118
38	Relevance of diagnostic investigations in chronic inflammatory demyelinating polyradiculoneuropathy: Data from the Italian CIDP database. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 152-161.	1.4	15
39	Bendamustine+rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. <i>Journal of the Neurological Sciences</i> , 2020, 413, 116777.	0.3	9
40	The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	36
41	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. <i>HemaSphere</i> , 2020, 4, e395.	1.2	4
42	POEMS syndrome. , 2020, , 129-143.		1
43	Limitations in daily activities and general perception of quality of life: Long term follow-up in patients with anti-myelin glycoprotein antibody polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 276-282.	1.4	5
44	Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 298-303.	1.4	11
45	Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2067-2070.	0.6	13
46	Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 111-119.	1.4	20
47	Beriberi neuropathy in oncological setting. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 162-163.	1.4	0
48	Peripheral nervous system involvement in lymphomas. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 5-18.	1.4	44
49	Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin associated glycoprotein antibody polyneuropathy. <i>European Journal of Neurology</i> , 2019, 26, 371-375.	1.7	15
50	Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 125-132.	0.9	108
51	Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2018, 36, 366-369.	0.8	6
52	Ultrasound in the evaluation of neuromuscular complications of radiation therapy. <i>Muscle and Nerve</i> , 2018, 57, E104-E105.	1.0	1
53	Different nerve ultrasound patterns in charcot-marie-tooth types and hereditary neuropathy with liability to pressure palsies. <i>Muscle and Nerve</i> , 2018, 57, E18-E23.	1.0	28
54	Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies. <i>Journal of Neurology</i> , 2018, 265, 2927-2933.	1.8	12

#	ARTICLE	IF	CITATIONS
55	Possible neuroleukemiosis in two patients with acute myeloid leukemia in complete bone marrow remission. <i>Journal of the Neurological Sciences</i> , 2018, 392, 63-64.	0.3	4
56	High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats. <i>Journal of Neuroinflammation</i> , 2018, 15, 232.	3.1	39
57	Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2017, 96, 159-161.	0.8	15
58	IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 1094-1097.	0.9	28
59	New technologies for the assessment of neuropathies. <i>Nature Reviews Neurology</i> , 2017, 13, 203-216.	4.9	90
60	Nerve ultrasound abnormalities mirror the course of varicella zoster virus sensory-motor radiculoplexopathy. <i>Muscle and Nerve</i> , 2017, 55, E16-E18.	1.0	2
61	Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. <i>Haematologica</i> , 2017, 102, e140-e143.	1.7	17
62	Anti-sulfatide/galactocerebroside antibodies in immunoglobulin M paraproteinemic neuropathies. <i>European Journal of Neurology</i> , 2017, 24, 1334-1340.	1.7	9
63	Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. <i>British Journal of Haematology</i> , 2017, 179, 748-755.	1.2	55
64	Nerve ultrasound and 3D-MR neurography suggestive of intraneural perineurioma. <i>Neurology</i> , 2016, 86, 1169-1170.	1.5	8
65	Isaacs syndrome with overlapping myopathy as the first manifestation of AL amyloidosis. <i>Journal of Neurology</i> , 2016, 263, 2332-2335.	1.8	2
66	Lenalidomide long-term neurotoxicity. <i>Neurology</i> , 2016, 87, 1161-1166.	1.5	31
67	Whipple's disease without gastrointestinal symptoms: a challenging diagnosis. <i>Journal of Neurology</i> , 2016, 263, 1657-1658.	1.8	1
68	Neuropathies associated with lymphoma. <i>Neuro-Oncology Practice</i> , 2015, 2, 167-178.	1.0	16
69	Polyneuropathy with anti-sulfatide and anti-MAG antibodies: Clinical, neurophysiological, pathological features and response to treatment. <i>Journal of Neuroimmunology</i> , 2015, 281, 1-4.	1.1	31
70	Neuroimaging in diagnosis of atypical polyradiculoneuropathies: report of three cases and review of the literature. <i>Journal of Neurology</i> , 2015, 262, 1714-1723.	1.8	22
71	Variations of the perforin gene in patients with chronic inflammatory demyelinating polyradiculoneuropathy. <i>Genes and Immunity</i> , 2015, 16, 99-102.	2.2	9
72	Pentraxin-3 and VEGF in POEMS syndrome: A 2-year longitudinal study. <i>Journal of Neuroimmunology</i> , 2014, 277, 189-192.	1.1	7

#	ARTICLE	IF	CITATIONS
73	Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. <i>Annals of Oncology</i> , 2014, 25, 257-264.	0.6	136
74	Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 392-398.	0.9	116
75	Clinical pattern and associations of oxaliplatin acute neurotoxicity. <i>Cancer</i> , 2013, 119, 438-444.	2.0	179
76	Malignant cell infiltration in the peripheral nervous system. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 115, 685-712.	1.0	26
77	Ischemic stroke as clinical onset of POEMS syndrome. <i>Journal of Neurology</i> , 2013, 260, 3178-3181.	1.8	17
78	Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). <i>European Journal of Cancer</i> , 2013, 49, 2910-2918.	1.3	35
79	Corneal confocal microscopy in patients with oxaliplatin-induced peripheral neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2013, 18, 269-271.	1.4	23
80	Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. <i>Cancer</i> , 2013, 119, 3570-3577.	2.0	86
81	Pachymeningeal involvement in POEMS syndrome: MRI and histopathological study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 33-37.	0.9	24
82	Neurophysiological examination of dorsal sural nerve. <i>Muscle and Nerve</i> , 2012, 46, 891-894.	1.0	18
83	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 899-902.	1.1	37
84	Pachymeningeal involvement in POEMS syndrome: Dramatic cerebral MRI improvement after lenalidomide therapy. <i>American Journal of Hematology</i> , 2012, 87, 539-541.	2.0	12
85	Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 306-308.	0.9	106
86	Occurrence and characterization of Pain in immune-mediated neuropathies: a multicentre prospective study. <i>European Journal of Neurology</i> , 2011, 18, 177-183.	1.7	12
87	Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. <i>European Journal of Neurology</i> , 2011, 18, 1417-1421.	1.7	71
88	Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. <i>Journal of the Peripheral Nervous System</i> , 2011, 16, 119-129.	1.4	68
89	Vascular endothelial growth factor helps differentiate neuropathies in rare plasma cell dyscrasias. <i>Muscle and Nerve</i> , 2011, 43, 164-167.	1.0	35
90	Spectrum of paraneoplastic disease associated with lymphoma. <i>Neurology</i> , 2011, 76, 705-710.	1.5	171

#	ARTICLE	IF	CITATIONS
91	Anti-ganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies. <i>Journal of Neuroimmunology</i> , 2010, 219, 119-122.	1.1	49
92	A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. <i>European Journal of Neurology</i> , 2010, 17, 289-294.	1.7	115
93	Improvement of peripheral nervous system manifestations of B-cell non-Hodgkin's lymphoma after rituximab therapy. <i>Journal of the Peripheral Nervous System</i> , 2009, 14, 146-148.	1.4	8
94	LONG-TERM EFFECT OF RITUXIMAB IN ANTI-MAG POLYNEUROPATHY. <i>Neurology</i> , 2008, 71, 1742-1744.	1.5	75
95	Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. <i>Journal of the Peripheral Nervous System</i> , 2007, 12, 102-107.	1.4	98
96	Development of a mantle cell lymphoma in an ATM heterozygous woman after occupational exposure to ionising radiation and somatic mutation of the second allele. <i>Leukemia Research</i> , 2006, 30, 1193-1196.	0.4	3
97	Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. <i>Brain</i> , 2005, 128, 1911-1920.	3.7	216
98	Rituximab-responsive CIDP. <i>European Journal of Neurology</i> , 2004, 11, 788-788.	1.7	53
99	Pegylated alpha-interferons peripheral neurotoxicity: prospective study in chronic hepatitis C. <i>Journal of the Peripheral Nervous System</i> , 2004, 9, 110-111.	1.4	0
100	Thalidomide neurotoxicity. <i>Neurology</i> , 2004, 62, 2288-2290.	1.5	71
101	Radiological evidence of subclinical dysphagia in motor neuron disease. <i>Journal of Neurology</i> , 1998, 245, 211-216.	1.8	56
102	Chronic inflammatory demyelinating polyneuropathy. <i>Neuromuscular Disorders</i> , 1996, 6, 311-325.	0.3	39